Synovial Sarcoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Imm

Synovial Sarcoma Pipeline constitutes 15+ key companies continuously working towards developing 20+ Synovial Sarcoma treatment therapies, analyzes DelveInsight.

Synovial Sarcoma Overview:

Synovial sarcoma is a rare soft tissue sarcoma that typically develops near joints or tendons, most commonly in the arms and legs, though it can occur elsewhere. Despite its name, it does not originate from synovial tissue but is associated with a specific genetic mutation-a translocation between chromosomes X and 18 (t(X;18))-which leads to abnormal tumor growth.

This cancer mainly affects adolescents and young adults (ages 15-40), with a slight male predominance. It often grows slowly, making early detection difficult. Symptoms include swelling, a palpable mass near a joint, pain, and tenderness. In advanced stages, it may affect surrounding muscles, nerves, or bones, leading to joint dysfunction and restricted movement.

Request for a detailed insights report on Synovial Sarcoma pipeline insights @ https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Synovial Sarcoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Synovial Sarcoma Therapeutics Market.

Key Takeaways from the Synovial Sarcoma Pipeline Report

DelveInsight's Synovial Sarcoma pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Synovial Sarcoma treatment.
Key Synovial Sarcoma companies such as Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar, and others are evaluating new drugs for Synovial Sarcoma to improve the treatment landscape.
Promising Synovial Sarcoma pipeline therapies in various stages of development include OTSA101, Tazemetostat, AL3818, and others.

Recent breakthroughs in the Synovial Sarcoma Pipeline Segment:

Following the approval of Tecelra, Adaptimmune Therapeutics is exploring additional applications of its TCR technology. In February 2025, the company announced that the FDA granted Breakthrough Therapy Designation to letetresgene autoleucel (lete-cel) for the treatment of myxoid/round cell liposarcoma (MRCLS), indicating potential for further advancements in sarcoma treatment.
On August 2, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tecelra (afamitresgene autoleucel) for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy. Tecelra is the first gene therapy approved for this patient population and the first engineered T-cell receptor (TCR) therapy authorized for a solid tumor.

Synovial Sarcoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Synovial Sarcoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Synovial Sarcoma market.

Download our free sample page report on Synovial Sarcoma pipeline insights @ https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Synovial Sarcoma Emerging Drugs

AL3818: Advenchen Laboratories
Tazemetostat: Ipsen
OTSA101: OncoTherapy Science

Synovial Sarcoma Companies

Over 15 key companies are actively developing therapies for Synovial Sarcoma. Among them, Advenchen Laboratories has a drug candidate in the most advanced stage of development, Phase III.

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Synovial Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Synovial Sarcoma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Synovial Sarcoma Therapies and Key Companies: Synovial Sarcoma Clinical Trials and advancements @ https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Synovial Sarcoma Pipeline Therapeutic Assessment
• Synovial Sarcoma Assessment by Product Type
• Synovial Sarcoma By Stage
• Synovial Sarcoma Assessment by Route of Administration
• Synovial Sarcoma Assessment by Molecule Type

Download Synovial Sarcoma Sample report to know in detail about the Synovial Sarcoma treatment market @ Synovial Sarcoma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Synovial Sarcoma Current Treatment Patterns
4. Synovial Sarcoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Synovial Sarcoma Late-Stage Products (Phase-III)
7. Synovial Sarcoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Synovial Sarcoma Discontinued Products
13. Synovial Sarcoma Product Profiles
14. Synovial Sarcoma Key Companies
15. Synovial Sarcoma Key Products
16. Dormant and Discontinued Products
17. Synovial Sarcoma Unmet Needs
18. Synovial Sarcoma Future Perspectives
19. Synovial Sarcoma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Synovial Sarcoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.